Brivaracetam Disposition in Mild to Severe Hepatic Impairment
The DOI matches its Crossref record.
Abstract
Brivaracetam is a high‐affinity synaptic vesicle protein 2A (SV2A) ligand in clinical development for epilepsy. This open‐label, single‐dose study evaluated brivaracetam disposition in participants with different degrees of hepatic impairment versus matched healthy controls. Twenty‐six participants (38–72 years; 19 males and 7 females) with hepatic impairment classified by Child‐Pugh score (mild, n = 6; moderate, n = 7; severe, n = 7) or normal hepatic function (n = 6) received a single oral dose of 100 mg brivaracetam. The pharmacokinetics of brivaracetam and its three main metabolites (acid, hydroxy, hydroxyacid) were determined and correlated with impairment severity. Dynamic liver function tests correlated with hepatic impairment severity. The plasma half‐life of brivaracetam was 9.8, 14.2, 16.4, and 17.4 hours and the area under the plasma concentration‐time curve was 29.7, 44.6, 46.7, and 47.1 µg h/mL in healthy controls and participants with mild, moderate, and severe liver impairment, respectively. Production of the acid metabolite was increased and the hydroxylated metabolites were decreased in participants with hepatic impairment versus healthy controls. Exposure to brivaracetam increased by 50–60% in patients with hepatic impairment, irrespective of severity. The relative importance of biotransformation pathways was altered; cytochrome P450 (CYP)‐dependent hydroxylation decreased; CYP‐independent acid metabolite formation increased concomitantly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.01.001 · Cited by 174
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“Metabolic clearance of BRV is reduced in patients with hepatic impairment, resulting in increased BRV exposure in mild, moderate, and severe liver disease of 50%–60%.(78) This requires a BRV dose reduction of up to half in patients with liver impairment of any severity.”
BackgroundWu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Klein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
Metadata
- Authors
- Stockis, A., Sargentini‐Maier, M. L., & Horsmans, Y.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-05-03
- Volume
- 53
- Issue
- 6
- Pages
- 633-641
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1659275768
- Cited by
- 49
- References
- 0
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.